Vaccination with cytokines in autoimmune diseases

Annals of Medicine

Volumn 40, Issue 5, 2008, Pages 343-351

  Delavallée, Laure ^a,b   Assier, Eric ^a,b   Denys, Anne ^a,b   Falgarone, Géraldine ^a,b,c   Zagury, Jean François ^d   Muller, Sylvianne ^e   Bessis, Natacha ^a,b   Boissier, Marie Christophe ^a,b,c,f  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c AVICENNE HOSPITAL   (France)

^d Bioinformatique et Chimie Moléculaire   (France)

^e CNRS   (France)

^f NONE   (France)

Author keywords

Autoimmune diseases; Cytokines; Vaccination

Indexed keywords

ADALIMUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; CYTOKINE; DACLIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY; PANITUMUMAB; RANIBIZUMAB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AUTOANTIBODY; DNA VACCINE;

ALLERGY; ALLOGRAFT; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CROHN DISEASE; DNA IMMUNIZATION; IMMUNE RESPONSE; MUSCLE ATROPHY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; ANIMAL; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG SCREENING; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; VACCINATION; VACCINES, DNA;

EID: 44949133037     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890801995298     Document Type: Review

References (49)

1. Lang KS, Burow A, Kurrer M, Lang PA, Recher M. The role of the innate immune response in autoimmune disease. J Autoimmun. 2007;29:206-12.
2. Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 2002;13:299-313.
3. Oppenheim JJ, Feldmann M. Introduction to the role of cytokines in innate host defense and adaptive immunity. In: Oppenheim JJ, Feldmann M, editors. Cytokine Reference, Vol 1: Ligands. London: Academic Press, 2000. p. 3-20.
4. Baggiolini M. Reflections on chemokines. Immunol Rev. 2000;177:5-7.
5. Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003;115:390-7.
6. Bessis N, Boissier MC. Gene therapy for patients with rheumatoid arthritis. Joint Bone Spine. 2006;73:169-76.
7. Falgarone G, Duclos M, Boissier MC. TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice. Joint Bone Spine. 2007;74:523-6.
8. Sayegh MH, Carpenter CB. Transplantation 50 years later - progress, challenges, and promises. N Engl J Med. 2004;351:2761-6.
9. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989;86:10029-33.
10. Chatenoud L. Monoclonal antibody-based strategies in autoimmunity and transplantation. Methods Mol Med. 2005;109:297-328.
11. Zagury D, Le Buanec H, Bizzini B, Burny A, Lewis G, Gallo RC. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev. 2003;14:123-37.
12. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov. 2004;3:81-8.
13. Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y, et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007;581:2017-21.
14. Choo-Kang BS, Hutchison S, Nickdel MB, Bundick RV, Leishman AJ, Brewer JM, et al. TNF-blocking therapies: an alternative mode of action? Trends Immunol. 2005;26:518-22.
15. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025-31.
16. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819-36.
17. Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine. 2007;74:148-54.
18. Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest. 1996;97:2833-41.
19. Bloquel C, Bessis N, Boissier MC, Scherman D, Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther. 2004;15:189-201.
20. Edwards CJ. Immunological therapies for rheumatoid arthritis. Br Med Bull. 2005;73-74:71-82.
21. Dalum I, Butler DM, Jensen MR, Hindersson P, Steinaa L, Waterston AM, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol. 1999;17:666-9.
22. Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, L'Hermenier C, et al. Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer. Cancer Immunol Immunother. 2005;54:848-57.
23. Wildbaum G, Youssef S, Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J Immunol. 2000;165:5860-6.
24. Shen Y, Chen J, Zhang X, Wu X, Xu Q. Human TNF-alpha gene vaccination prevents collagen-induced arthritis in mice. Int Immunopharmacol. 2007;7:1140-9.
25. He X, Tsang TC, Zhang T, Luo P, Harris DT. Antigen epitope-expressing cytokines for DNA immunization. Vaccine. 2005;23:1966-72.
26. Spohn G, Guler R, Johansen P, Keller I, Jacobs M, Beck M, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol. 2007;178:7450-7.
27. Le Buanec H, Delavallee L, Bessis N, Paturance S, Bizzini B, Gallo R, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A. 2006;103:19442-7.
28. Capini CJ, Bertin-Maghit SM, Bessis N, Haumont PM, Bernier EM, Muel EG, et al. Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine. 2004;22:3144-53.
29. Blaser C. Media Release - Cytos Biotechnology reports results from a phase I/IIa study with CYT007-TNFQb for the treatment of psoriasis. Cytos Biotechnology. 2007. Available at: http://www.cytos.com/doc/ 070524_Cytos_Press_E.pdf.
30. Bertin-Maghit SM, Capini CJ, Bessis N, Chomilier J, Muller S, Abbas A, et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine. 2005;23:4228-35.
31. Svenson M, Hansen MB, Thomsen AR, Diamant M, Nansen A, Rieneck K, et al. Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha. J Immunol Methods. 2000;236:1-8.
32. Miossec P. IL-17 in rheumatoid arthritis: a new target for treatment or just another cytokine? Joint Bone Spine. 2004;71:87-90.
33. Sonderegger I, Rohn TA, Kurrer MO, Iezzi G, Zou Y, Kastelein RA, et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol. 2006;36:2849-56.
34. Rohn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 2006;36:2857-67.
35. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol. 2006;36:2868-74.
36. Bossu P, Neumann D, Del Giudice E, Ciaramella A, Gloaguen I, Fantuzzi G, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci U S A. 2003;100:14181-6.
37. Nabors GS, Farrell JP. Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses. Infect Immun. 1994;62:5498-504.
38. Yang J, Torio A, Donoff RB, Gallagher GT, Egan R, Weller PF, et al. Depletion of eosinophil infiltration by anti-IL-5 monoclonal antibody (TRFK-5) accelerates open skin wound epithelial closure. Am J Pathol. 1997;151:813-9.
39. Yang G, Li L, Volk A, Emmell E, Petley T, Giles-Komar J, et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther. 2005;313:8-15.
40. Hertz M, Mahalingam S, Dalum I, Klysner S, Mattes J, Neisig A, et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol. 2001;167:3792-9.
41. Tan GH, Wang CC, Huang FY, Wang H, Huang YH, Lin YY. Active immunotherapy of allergic asthma with a recombinant human interleukin-5 protein as vaccine in a murine model. Chin Med J (Engl). 2007;120:1517-22.
42. Le Buanec H, Paturance S, Couillin I, Schnyder-Candrian S, Larcier P, Ryffel B, et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine. 2007;25:7206-16.
43. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation. 2005;112:1054-62.
44. Uyttenhove C, Arendse B, Stroobant V, Brombacher F, Van Snick J. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol. 2004;34:3572-81.
45. Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A. 2007;104:2837-42.
46. Dyer MR, Renner WA, Bachmann MF. A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today. 2006;11:1028-33.
47. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11-20.
48. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol. 2005;174:1580-6.
49. Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, et al. Site-specific UBITh((R)) amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine. 2007;25:3041-52.